Insulin Resistance and Hyperinsulinemia Are Related to Plasma Aldosterone Levels in Hypertensive Patients
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—An association between aldosterone and insulin resistance has been demonstrated in obesity and primary aldosteronism and in blacks with the metabolic syndrome. The aim of this study was to evaluate the relationship of plasma aldosterone with insulin sensitivity in white subjects. RESEARCH DESIGN AND METHODS—In 356 patients with essential hypertension and 102 normotensive control subjects of comparable age and BMI, we measured, after discontinuation of treatment, plasma active renin, aldosterone, cortisol, glucose, insulin, and C-peptide levels and calculated markers of insulin sensitivity. Direct assessment of insulin sensitivity was obtained in a subset of 64 hypertensive patients by a hyperinsulinemic clamp. RESULTS—Hypertensive patients had significantly greater fasting plasma insulin and C-peptide concentrations and homeostasis model assessment (HOMA) indexes than normotensive control subjects. A positive association with increasing plasma aldosterone concentrations was demonstrated for plasma glucose, insulin, C-peptides, and HOMA. Assessment of insulin sensitivity by clamp showed a significant decrease of the metabolic clearance rate of glucose with increasing aldosterone levels. Significant correlations were found between plasma aldosterone, plasma insulin, and C-peptide levels, HOMA, and glucose metabolic clearance rate. Blood pressure and plasma potassium, plasma cortisol, and renin levels, but not BMI, were also directly correlated with plasma aldosterone. Multiple regression analysis showed that HOMA, together with plasma potassium, cortisol, and renin levels, was independently correlated with plasma aldosterone. CONCLUSIONS—This study demonstrates a direct relationship between aldosterone, insulin resistance, and hyperinsulinemia in white subjects. In patients with hypertension, this relationship might contribute to maintenance of high blood pressure and increased cardiovascular risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary aldosteronism (PA) is associated with increased risk for dysglycemia.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [13]
In the citing paper
“However, the effects of hyperaldosteronism on insulin sensitivity and β-cell function are unclear.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [13]
In the citing paper
“These assessments do not provide a robust estimation of insulin sensitivity when used alone.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [13]
In the citing paper
“However, when compared with normotensive cohorts, reduced insulin sensitivity has been reported in PA patients [19,9,20,13,8,21,22].”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [13]
Citations
Cites
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Insulin Resistance in Essential Hypertension
Ferrannini, E., Buzzigoli, G., Bonadonna, R., Giorico, M. A., Oleggini, M., Graziadei, L., Pedrinelli, R., Brandi, L., & Bevilacqua, S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708063170605 · Cited by 2,344
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699
Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.
Modan, M., Halkin, H., Almog, S., Lusky, A., Eshkol, A., Shefi, M., Shitrit, A., & Fuchs, Z. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111776 · Cited by 1,465
Triggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201
Effect of Insulin and Glucose Infusions on Sympathetic Nervous System Activity in Normal Man
Rowe, J. W., Young, J. B., Minaker, K. L., Stevens, A. L., Pallotta, J., & Landsberg, L. (1981) · Diabetes · doi:10.2337/diab.30.3.219 · Cited by 1,143
Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.
Anderson, E. A., Hoffman, R. P., Balon, T. W., Sinkey, C. A., & Mark, A. L. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115260 · Cited by 1,075
Mulatero (2004) · doi:10.1210/jc.2003-031337 · Cited by 961
The Effect of Weight Loss on the Sensitivity of Blood Pressure to Sodium in Obese Adolescents
Rocchini, A. P., Key, J., Bondie, D., Chico, R., Moorehead, C., Katch, V., & Martin, M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908313210905 · Cited by 621
Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive Persons
Vasan, R. S., Evans, J. C., Larson, M. G., Wilson, P. W. F., Meigs, J. B., Rifai, N., Benjamin, E. J., & Levy, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033263 · Cited by 571
Cited by
Items 101–155 of 155
Zhu, Q., & Zhu, F. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14607 · Cited by 7
Dangmann, R. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111136 · Cited by 6
Epithelial sodium channels: contributions to the regulation of vascular function and blood pressure
Jia, G., Whaley‐Connell, A. T., & Hill, M. A. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00504.2025 · Cited by 6
Bu, X., Sun, F., Zhang, H., Liu, X., Zhao, Z., He, H., Li, Y., Yan, Z., & Zhu, Z. (2022) · Journal of Diabetes Research · doi:10.1155/2022/8932133 · Cited by 6
El-Domiaty, H. F., Sweed, E. M., Kora, M. A. M., Zaki, N. G., & Khodir, S. A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.904756 · Cited by 5
Shevelok, A. N. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-3991 · Cited by 5
Perciaccante, A., Fiorentini, A., Valente, R., Stefano, A. D., & Tubani, L. (2007) · Diabetes Care · doi:10.2337/dc07-1176 · Cited by 5
Interactions between CKD and MetS and the Development of CVD
Aihara, K., Mogi, M., Shibata, R., Bishop‐Bailey, D., & Ma, X. L. (2011) · Cardiology Research and Practice · doi:10.4061/2011/878065 · Cited by 5
Role of Aldosterone in Insulin Resistance: Fact of Fantasy
Sechi, L. A., & Colussi, G. (2015) · Endocrinology & Metabolic Syndrome · doi:10.4172/2161-1017.1000161 · Cited by 4
Self-citationEplerenone–A novel Mineralocorticoid receptor antagonist for the clinical application
Wu, N., Zhang, Y.-Y., & Zhao, D. (2022) · Environmental Disease · doi:10.4103/ed.ed_7_21 · Cited by 4
Roles of Aldosterone Receptor Antagonists in Heart Failure, Hypertension, and Chronic Kidney Disease
Wang, A., Elshehadeh, R., Rao, D., Yap, E., Lee, A. E., Mossobir, F., Yu, J. J., Braaton, K., & Nguyen, T. V. (2016) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2015.10.023 · Cited by 4
Zhang, C., Jiang, Y., Su, T., Jiang, L., Zhou, W., Zhong, X., Wu, L., & Wang, W. (2022) · Endocrine · doi:10.1007/s12020-022-03095-8 · Cited by 4
Epidemiology of Secondary Hypertension in Children
Bajracharya, P., Olivera, M. R., & Kapur, G. (2014) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-014-0388-3 · Cited by 4
Metabolic Dysfunction in Primary Aldosteronism
Sechi, L. A., Colussi, G., & Catena, C. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.132951 · Cited by 4
Self-citationKobayashi, M., Duarte, K., Ferreira, J. P., Baudry, G., Monzo, L., McMurray, J. J. V., van Veldhuisen, D. J., Pitt, B., Zannad, F. M., & Girerd, N. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70047 · Cited by 3
Mejía-Montilla, J., Reyna‐Villasmil, E., Torres-Cepeda, D., Santos-Bolívar, J., Reyna-Villasmil, N., & Bravo-Henríquez, A. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.09.003 · Cited by 4
Singh, J., Adel, F., Scott, C. G., & Chen, H. H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16073 · Cited by 3
Sołtysiak, M., Miazgowski, T., Jaroszyńska, E., Janowska, A., & Widecka, K. (2015) · Arterial Hypertension · doi:10.5603/ah.2015.0003 · Cited by 4
Kumar, A., Patel, D. R., Brennan, D. M., Wolski, K., Lincoff, A. M., Ruotolo, G., McErlean, E. S., Weerakkody, G. J., Riesmeyer, J. S., Nicholls, S. J., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013790 · Cited by 3
AlSafar, H. S. (2013) · International Journal of Genetics and Molecular Biology · doi:10.5897/ijgmb2013.0068 · Cited by 2
Colussi, G., Catena, C., Lapenna, R., Nadalini, E., Chiuch, A., & Sechi, L. A. (2007) · Diabetes Care · doi:10.2337/dc07-1344 · Cited by 2
Self-citationAutosomal dominant polycystic kidney disease and hypertension masquerading primary aldosteronism
Mital, P., Abhijit, K., & Shishir, G. (2017) · Indian Journal of Nephrology · doi:10.4103/ijn.ijn_330_16 · Cited by 1
Metabolic effects of aldosterone
Валерьевна, И. К., Mazurina, N. V., Platonova, N. M., & Troshina, E. A. (2024) · Obesity and metabolism · doi:10.14341/omet13040 · Cited by 1
Han, M., Cao, X., Zhang, J., Yang, X., Zhang, Y., & Liu, Y. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s457243 · Cited by 1
Ohkura, T., Taniguchi, S., Inoue, K., Yamamoto, N., Matsuzawa, K., Fujioka, Y., Sumi, K., Izawa, S., Takechi, M., Osaki, Y., et al. (2009) · Yonago acta medica · Cited by 1
Gv, K., Goncharov, N. P., & Chagina, N. A. (2011) · Problems of Endocrinology · doi:10.14341/probl20115747-12 · Cited by 2
Aldosterone and Cardiovascular Diseases
Tomaschitz, A., & Pilz, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0509-6_12
Huang, C., Wang, W., Chien, H.-Y., Hsu, Y.-H., & Hsia, C. (2012) · 內科學誌 · doi:10.6314/jimt.2012.23(4).08
Diabetes in Hyperaldosteronism
Crudo, V. L., Mulatero, P., Monticone, S., & Veglio, F. (2014) · Frontiers in diabetes · doi:10.1159/000357246
Primary aldosteronism: an update
Freel, E. M., & Connell, J. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.10
Lalić, T. (2013) · Medicinski glasnik Specijalna bolnica za bolesti stitaste zlezde i bolesti metabolizma Zlatibor · doi:10.5937/medgla1348044l
Dantas, A. C. S. (2013) · Americanae (AECID Library)
3) Aldosterone and Adult Disease
Nagase, M., & Fujita, T. (2008) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.97.2160
Capeletti, J. T., Barbosa, R. R., Cestari, P. F., Peres, G., Ibañez, T. L. P., Gonzaga, C. C., de Sousa, M. G., Passarelli, O., Borelli, F. A. O., & Amodeo, C. (2009) · Cited by 1
Differential Effects of Two Antialdosterone Agents on Glycemic Control
Garg, R., & Adler, G. K. (2016) · Endocrinology · doi:10.1210/en.2016-1656
Kimura, Y., Matsui, J., Matsumura, K., Murakami, H., Yamashita, M., Tanabe, J., Tamasawa, N., & Daimon, M. (2014) · Institutional Repositories DataBase (IRDB)
Targeting obesity-related inflammation through nutritional and genetic approaches
LeMieux, M. J. (2015) · ThinkTech (Texas Tech University)
Koval, S. M., Miloslavsky, D. К., Снегурская, И. А., Мысниченко, О. В., & Penkova, M. Y. (2017) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.13.5.2017.110026
Aldosterone and the mineralocorticoid receptor in insulin resistance and diabetes
Toloza, F. J. K., & Mendivil, C. O. (2017) · Alad · doi:10.24875/alad.m17000001
Current literature in diabetes
(2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.879
(2009) · Wiley eBooks · doi:10.1002/9781444317176.refs
Sch�tten (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190620ms
Study on the Association between Primary Aldosteronism and Cerebrovascular Disease
阿依努尔, ·. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13102355
Azayzeh, W., Alfreahat, A., Khader, K. O., Almasri, M.-S., Mahmoud, L. M., Alsarayreh, M., Jankhout, S., Alqaisi, R. O., Alzawahreh, S., Salah, D. W., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3823797/v1
Addressing a Key Metabolic Component of PCOS: Insulin
Hopkins, D., & Chappell, A. (2025) · Obstetrics and gynecology. · doi:10.5772/intechopen.1010981
Ye, L., Wu, Y., Wei, H., Liang, X., Lin, J., Huang, S., Mo, Z., & Li, M. (2026) · Endocrine · doi:10.1007/s12020-026-04571-1
DPA/AA ratio as a potential biomarker of primary aldosteronism in young and middle-aged adults
Xie, W., Lin, R., Meng, Y., Zhang, L., Zheng, Z., & Zhang, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1771955
Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction
Kobayashi, M., Pitt, B., & Zannad, F. M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag578
Sánchez‐Bayuela, T., Barrera‐Chimal, J., & Jaisser, F. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01125-6 · Cited by 1
Mahgoub, S. S., Dwairi, R., Al-saraireh, Y. M., Eyalsalman, M. M., Alkhamaiseh, S., Gharaibeh, B., Abuhalimeh, S., Abdullah, H., Kaswal, M., & Zaghloul, A. A. Z. (2026) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3514
Li, P., Zhang, Z., Qin, Y., Liang, X., Mo, Y., & Chen, D. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261496807
Metadata
- Authors
- Colussi, G., Catena, C., Lapenna, R., Nadalini, E., Chiuch, A., & Sechi, L. A.
- Affiliations
- University of Udine (IT)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-09-01
- Volume
- 30
- Issue
- 9
- Pages
- 2349-2354
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2109111616
- Cited by
- 155
- References
- 47
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 4 · 2017: 6 · 2016: 6 · 2015: 11 · 2014: 11 · 2013: 9 · 2012: 10
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Funders
- Società Italiana dell'Ipertensione Arteriosa
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- insulin resistance, hyperinsulinemia, plasma aldosterone, essential hypertension, insulin sensitivity, C-peptide, HOMA, hyperinsulinemic-euglycemic clamp, glucose metabolic clearance rate, renin, cortisol, plasma potassium, cardiovascular risk
- MeSH terms
- Aged, Aldosterone, Cross-Sectional Studies, Female, Glucose, Humans, Hyperinsulinism, Hypertension, Insulin Resistance, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.